CDXC Jun 2024 2.500 call
| Previous close | 0.9000 |
| Open | 1.0000 |
| Bid | 0.0000 |
| Ask | 2.6500 |
| Strike | 2.50 |
| Expiry date | 2024-06-21 |
| Day's range | 0.9000 - 1.0000 |
| Contract range | N/A |
| Volume | |
| Open interest | 5 |
Business WireMilestone Phase II Clinical Study Demonstrates Niagen®, Patented Nicotinamide Riboside (NR), Improves Functional Mobility for Individuals with Peripheral Artery Disease (PAD)
LOS ANGELES, June 24, 2024--ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research, shares results from a milestone phase II clinical study showcasing the promising effects of nicotinamide riboside (NR) supplementation for people with peripheral artery disease (PAD). This study was part of the ChromaDex External Research Program (CERP®), which donated ChromaDex’s patented NR ingredient, Niagen®, the most efficient and high-quality NAD+ precursor,
Simply Wall St.Here's Why We Think ChromaDex Corporation's (NASDAQ:CDXC) CEO Compensation Looks Fair
Key Insights ChromaDex to hold its Annual General Meeting on 20th of June Total pay for CEO Rob Fried includes...
Business WireChromaDex to Launch Niagen+, the First-Of-Its-Kind Pharmaceutical-Grade Intravenous and Injectable Niagen® (Patented Nicotinamide Riboside Chloride or NRC)
LOS ANGELES, June 13, 2024--ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research and its application to healthy aging, unveils Niagen+, the first-of-its-kind pharmaceutical-grade Niagen® (patented nicotinamide riboside chloride or NRC). Authorized by the U.S. FDA for compounding by 503B outsourcing facilities, pharmaceutical-grade intravenous (IV) and injectable NRC will be available in IV, shot, and push forms exclusively at clinics, with a pr
